Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A9BZ
|
||||
| Former ID |
DNC006739
|
||||
| Drug Name |
PSB-601
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [530243] | ||
| Formula |
C25H28N6O4S
|
||||
| Canonical SMILES |
CCCN1C(=O)C2=C(NC1=O)N=C(N2)C3=CC=C(C=C3)S(=O)(=O)N4CCN<br />(CC4)CC5=CC=CC=C5
|
||||
| InChI |
1S/C25H28N6O4S/c1-2-12-31-24(32)21-23(28-25(31)33)27-22(26-21)19-8-10-20(11-9-19)36(34,35)30-15-13-29(14-16-30)17-18-6-4-3-5-7-18/h3-11H,2,12-17H2,1H3,(H,26,27)(H,28,33)
|
||||
| InChIKey |
HHNGYTVWOXXKET-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [530243] | |
| Adenosine A2b receptor | Target Info | Inhibitor | [530966] | ||
| Adenosine A2a receptor | Target Info | Inhibitor | [530243] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Alcoholismhsa04015:Rap1 signaling pathway | |||||
| Parkinson's disease | |||||
| Alcoholism | |||||
| Pathway Interaction Database | C-MYB transcription factor networkhif2pathway:HIF-2-alpha transcription factor network | ||||
| References | |||||
| Ref 530243 | J Med Chem. 2009 Jul 9;52(13):3994-4006.1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. | ||||
| Ref 530966 | Eur J Med Chem. 2010 Aug;45(8):3459-71. Epub 2010 May 7.Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.